Clinical trialNCT00388505CompletedPhase 3Interventional

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

SponsorNovartis PharmaceuticalsEnrollment517Cystic Fibrosis

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Michael Konstan, MD
University Hospitals Cleveland Medical Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

72 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Novartis Investigative Site
South Brisbane, Australia

Canada

Novartis Investigative Site
Calgary, Canada
Novartis Investigative Site
Hamilton, Canada
Novartis Investigative Site
Ste-Foy, Canada
Novartis Investigative Site
Vancouver, Canada

Chile

Novartis Investigative Site
Santiago, Chile

Colombia

Novartis Investigative Site
Baranquilla, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Cali, Colombia
Novartis Investigative Site
Medellín, Colombia

France

Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Rouen, France

Germany

Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Essen, Germany
Klinikum Der Johann-Wolfgang-Goethe-Universitaet
Frankfurt, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hanover, Germany
Ludwig-Maximilians-Universitaet
Munich, Germany
Novartis Investigative Site
München, Germany

Hungary

Novartis Investigative Site
Hungary, Hungary
Novartis Investigative Site
Kaposvár, Hungary

Israel

Novartis Investigative Site
Haifa, Israel
Novartis Investigative Site
Jerusalem, Israel
Novartis Investigative Site
Petah Tikva, Israel

Italy

Novartis Investigator Site
Genoa, Italy
Novartis Investigative Site
Palermo, Italy
Novartis Investigative Site
Potenza, Italy
Novartis Investigative Site
Roma, Italy

Mexico

Novartis Investigative Site
Monterrey Nuevo Leon, Mexico

Netherlands

Novartis Investigative Site
Groesbeek, Netherlands
Novartis Investigative Site
Rotterdam, Netherlands

Spain

Novartis Investigative Site
Barakaldo, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Málaga, Spain

32 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Feb 2006
Primary completion: 31 Mar 2009
Completion: 31 Mar 2009
Last update posted: 24 Jul 2012
Registered enrollment: 517
Registry id: NCT00388505

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.